Tag Archives: Kenneth Chan

Who’s running the life science companies’ public relations campaign in British Columbia (Vancouver, Canada)?

I started writing this in the aftermath of the 2021 Canadian federal budget when most of the action (so far) occurred but if you keep going to the end of this post you’ll find updates for Precision Nanosystems and AcCellera and a few extra bits. Also, you may want to check out my August 20, 2021 posting (Getting erased from the mRNA/COVID-19 story) about Ian MacLachlan and some of the ‘rough and tumble’ of the biotechnology scene in BC/Canada. Now, onto my analysis of the life sciences public relations campaign in British Columbia.

Gordon Hoekstra’s May 7, 2021 article (also in print on May 8, 2021) about the British Columbia (mostly in Vancouver) biotechnology scene in the Vancouver Sun is the starting point for this story.

His entry (whether the reporter realizes it or not) into a communications (or public relations) campaign spanning federal, provincial, and municipal jurisdictions is well written and quite informative. While it’s tempting to attribute the whole thing to a single evil genius or mastermind in answer to the question posed in the head, the ‘campaign’ is likely a targeted effort by one or more groups and individuals enhanced with a little luck.

Federal and provincial money for life sciences and technology

The Business Council of British Columbia’s April 22, 2021 Federal & B.C. Budgets 2021 Analysis (PDF), notes this in its Highlights section,

•Another priority reflected in both budgets is boosting innovation and accelerating the growth of technology-producing companies. The federal budget [April 19, 2021] is spending billions more to support the life sciences and bio-manufacturing industry, clean technologies, the development of electric vehicles, the aerospace sector, quantum computing, AI, genomics, and digital technologies, among others.

•B.C.’s budget [April 20, 2021] also provides funding to spur innovation, support the technology sector and grow locally-based companies. In this area the main item is the new InBC Investment Corporation [emphasis mine], first announced last summer. Endowed with $500 million financed via an agency loan, the Corporation will establish a fund to invest in growing and “anchoring” high-growth [emphasis mine] B.C. businesses.

Their in-depth analysis does not provide more detail about the life sciences investments in the 2021 Canadian federal budget or the 2021 BC provincial budget.

My May 4, 2021 posting details many of the Canadian federal investments in life sciences and other technology areas of interest. The 2021 BC budget announcement is so vague, it didn’t merit much more than this mention until now.

InBC Investment Corporation (BC’s contribution)

InBC Investment Corporation was set up on or about April 27, 2021 as three news ‘references’ (brief summaries with a link) suggest: InBC Investment Corp. Act, InBC Announcement, $500-million investment fund paves way for StrongerBC.

While the corporation does not have a specific mandate to fund the biotechnology sector, given the current enthusiasm, it’s easy to believe they might be more inclined to fund them than not, regardless of any expertise they or may not have specifically in that field.

Of most interest to me was InBC’s Board of Directors, which I tracked down to a BC Ministry of Jobs, Economic Recovery and Innovation May 6, 2021 news release,

InBC Investment Corp. now has a full board of directors with backgrounds in finance, economics, impact investing and business to provide strategic guidance and accountability for the new Crown corporation.

InBC will support startups [emphasis mine], help promising companies scale up and work with a “triple bottom line” mandate that considers people, the planet and profits, to position British Columbia as a front-runner in the post-pandemic economy.

Christine Bergeron, president and chief executive officer of Vancity, will serve as the new board chair of InBC Investment Corp. The nine-member board of directors is made up of both public and private sector members who are responsible for oversight of the corporation, including its mission, policies and goals.

The InBC board members were selected through a comprehensive process, guided by the principles of the Crown Agencies and Board Resourcing Office. Candidates with a variety of relevant backgrounds were considered to form a strong board consisting of seven women and two men. The members appointed represent diversity as well as appropriate areas of expertise.

The following people were selected as members on the board of directors:

  • Christine Bergeron, president and CEO, Vancity
  • Kevin Campbell, managing director of investment banking, board of directors, Haywood Securities
  • Ingrid Leong, VP finance for JH Investments and chief investment officer, Houssian Foundation
  • Glen Lougheed, serial tech entrepreneur and angel investor
  • Suzanne Trottier, vice-president of Indigenous trust services, First Nations Bank Trust
  • Carole James, former minister of finance and deputy premier, Government of British Columbia
  • Iglika Ivanova, senior economist, public interest researcher, BC Office of the Canadian Centre for Policy Alternatives
  • Bobbi Plecas, deputy minister, B.C.’s Ministry of Jobs, Economic Recovery and Innovation
  • Heather Wood, deputy minister, B.C.’s Ministry of Finance

Legislation to provide the governance framework for InBC was introduced by the legislative assembly on April 27, 2021.

Board experience at growing a startup?

This group of people doesn’t seem to have a shred of experience with startups. Glen Lougheed’s “serial tech entrepreneur and angel investor” description means nothing to me and the description he provides in his LinkedIn profile doesn’t clear up matters,

I am a product and business development professional with an entrepreneurial attitude and strong technical skills. I have been building companies both mine and others since I was a teenager.

Having looked up the two companies for which he is currently acting as Chief Executive Officer, Lougheed’s interest appears to be focused on the use of ‘big data’ in marketing and communications campaigns.

Perhaps startup experience isn’t necessary since the board has been appointed to do this (from the BC Ministry of Jobs, Economic Recovery and Innovation May 6, 2021 news release; click on the Backgrounder),

Responsibilities of the InBC Investment Corp. board of directors

The board of directors will be responsible for oversight of the management of the affairs of the corporation. This includes:

  • selecting and approving the chief executive officer and chief innovation officer and monitoring performance and accountabilities;
  • reviewing and approving annual corporate financial statements;
  • oversight of policies that relate to InBC’s mandate and holding the executive to account for its accountabilities with respect to InBC’s mandate;
  • oversight of InBC’s operations; and
  • selection and appointment of InBC’s auditor.

Relationships

So, we have two government civil servants, Wood (Deputy Minister of B.C.’s Ministry of Finance) and Plecas (Deputy Minister of B.C.’s Ministry of Jobs, Economic Recovery and Innovation), and James, a BC Minister of Finance, who left the job several months ago. Then we have Lougheed, recently resigned (May 2021) as special advisor on innovation and technology to the BC Minister of Jobs, Economic Recovery and Innovation.

It would seem almost half of this new board is or has been affiliated with the government and, likely, know each other.

I expect there are more relationships to be found but my interest is in the overall picture as it pertains to the biotechnology scene. This board (except possibly for Lougheed) does not seem to have any experience in the biotechnology sector or growing any sort of startup business in any technology field.

Presumably, the new chief executive officer (CEO) and new chief innovation officer (CIO) will have some of the necessary experience. Still, biotechnology isn’t the same as digital technology, an area where the BC technology community is quite strong. (The Canadian federal government’s Digital Technology Supercluster is headquartered in BC.)

I imagine the politics around who gets hired as CEO and as CIO will be quite interesting.

See the ‘Updates and extras’ at the end of this posting for more mention of this ‘secretive’ government corporation.

The BC biotech gorillas

AbCellera was BC’s biggest biotech story in 2020/21 (see my Avo Media, Science Telephone, and a Canadian COVID-19 billionaire scientist post from December 30, 2020 for more. Do check out the subsection titled “Avo Media …” for a look at an unexpectedly interlaced relationship). Note: The AbCellera COVID-19 treatment is not a vaccine or a vaccine delivery system.

It was a bit surprising that Acuitas Therapeutics didn’t get more attention although Hoekstra seems to have addressed that shortcoming in his May 7, 2021 article by using Thomas Madden and Acuitas as the hook for the story,

By early 2020, concern was mounting about a new, deadly coronavirus first detected in Wuhan, China.

The World Health Organization had declared the coronavirus outbreak a global health emergency just days before. There had been more than 400 deaths and more than 20,000 cases, most of those in China.

But the virus was spreading around the world. Deaths had occurred in Hong Kong and the Philippines, and the virus had been detected in the U.S. and Canada.

By early January of 2020, scientists in China had already sequenced the virus’s genome and made it public, allowing scientists to begin the research for a vaccine.

Scientists expected that could take years.

But, as a second case was confirmed in B.C. in early February, Thomas Madden, a world-renowned expert in nanotechnology who heads Vancouver-based biotech company Acuitas Therapeutics, flew to Germany. [emphases mine]

Acuitas was in the business of creating lipid nanoparticles, microscopic biological vehicles that could deliver drugs [emphasis mine] — for example, to specifically target cancers in the body.

Scientists are already beginning to say it’s likely that a booster vaccine will be needed [emphasis mine] next year to deal with the virus variants.

Madden, the head of Acuitas, says it makes absolute sense to use the new biotechnology, for example, the use of messenger RNA vaccines, to prepare and fight future pandemics.

Says Madden [emphasis mine]: “The technology in terms of what it’s able to do is absolutely phenomenal. It’s just taken us 40 years to get here.”

So, Hoekstra reminds us of the international nature and urgency of the crisis, then, introduces Acuitas as a vital and local player in solutions deployed internationally, and, finally, brings us back to Acuitas after providing an overview of the BC biotech scene and the federal and provincial government’s latest moves,

AbCellera Biologics is more of a supporting player, along with a number of other companies, in Hoekstra’s story,

Sandwiched in the middle, you’ll find what I think is the point of the story,

LifeSciences BC and the provincial government’s commitments

From Hoekstra’s May 7, 2021 article,

The importance of the biotech sector in providing protection against pandemics has caught the attention of the federal and B.C. governments. It has also been noticed by the private markets.

In its budget [April 19, 2021] earlier this month [sic], the federal government promised more than $2 billion in the next seven years to support “promising” life sciences and bio-manufacturing firms, research, training, education and vaccine candidates.

Some companies, including Precision NanoSystems, have already got federal funding. The Vancouver company received $18.2 million last year to help develop its self-replicating mRNA vaccine and another $25 million in early 2021 to assist building a $50-million facility to produce the vaccine.

Last fall, Symvivo received $2.8 million from the National Research Council to help develop its oral COVID-19 vaccine.

AbCellera has also received a pledge of $175.6 million to help build an accredited manufacturing facility in Vancouver [emphasis mine] to produce antibody treatments.

AbCellera expects to double its 230-person workforce over the next two years as it expands its Vancouver campus.

When AbCellera became a publicly traded company late last year, it raised more than $500 million and had a recent market capitalization, the value of its stock, of about $8.5 billion.

When the B.C. government delivered its throne speech recently, the contribution of the province’s life sciences sector in the fight against the COVID-19 pandemic was highlighted, with Precision NanoSystems, AbCellera and StarFish Medical getting mentions. “Their work will not only help bring us out of the pandemic, it will position our province for success in the years ahead,” said B.C.’s Lt. Gov. Jane Austen in delivering the throne speech.

When the budget was released the following week [April 20, 2021], B.C. Finance Minister Selina Robinson said a new three-year, $500-million strategic investment fund would help support and scale up tech firms.

Despite their successes, B.C. biotech firms have faced challenges.

SaNOtize had to go to the U.K. to get support for clinical trials and AbCellera has been disappointed that despite Health Canada emergency approval of its COVID-19 treatment, provinces have been reluctant to use Bamlanivimab.

Hansen, AbCellera’s CEO and a former University of B.C. professor with a PhD in applied physics and biotechnology, said he believes that biotech is the most important frontier of technology.

In the past, while great science was launched from B.C.’s universities, not as great a job was done on turning that science into innovation, jobs [emphasis mine] and the capacity to bring new products to market, possibly because of a lack of entrepreneurship and polices to make it more attractive to companies to grow and thrive here and move here, notes Hansen.

Hurlburt [Wendy Hurlburt], the LifeSciences B.C. CEO, says that policies, including tax structure and patenting [emphasis mine], that encourages innovation companies are needed to support the biotech sector.

But, adds Hansen: “Here in Vancouver, I feel like we’re turning the corner. There’s probably never been a time when Vancouver’s biotech sector [emphasis mine] was stronger. And the future looks very good.”

Not only is the province involved but so is the City of Vancouver (more about that in a bit).

It’s not all about the cash

Hoekstra’s May 7, 2021 article helped answer a question I had in the title of another posting, January 22, 2021: Why is Precision Nanosystems Inc. in the local (Vancouver, Canada) newspaper? (See the ‘Updates and extras’ at the end of this posting for more to the answer.)

This campaign has been building for a while. In the “Is it magic or how does the federal budget get developed? subsection of my May 4, 2021 posting on the 2021 Canadian federal budget I speculated a little bit,

I believe most of the priorities are set by power players behind the scenes. We glimpsed some of the dynamics courtesy of the WE Charity scandal 2020/21 and the SNC-Lavalin scandal in 2019.

Access to special meetings and encounters are not likely to be given to any member of the ‘great unwashed’ but we do get to see the briefs that are submitted in anticipation of a new budget. These briefs and meetings with witnesses are available on the Parliament of Canada website (Standing Committee on Finance (FINA) webpage for pre-budget consultations.

AbCellera submitted a brief dated August 7, 2020 (PDF) detailing how they would like to see the Income Tax Act amended. It’s not always about getting cash, although that’s very important. In this brief, the company wants “… improved access to the enhanced Scientific Research & Experimental Development tax credit.”

There are many aspects to these campaigns including the federal Income Tax Act and, in this case, municipal involvement.

Vancouver (city government) and the biotech sector

About five weeks prior to the 2021 Canadian federal budget and BC provincial budget announcements, there was some news from the City of Vancouver (from a March 10, 2021 article by Kenneth Chan for dailyhive.com), Note: Links have been removed,

Major expansion plans are abound for AbCellera over the next few years to the extent that the Vancouver-based biotechnology company is now looking to build a massive purpose-built office and medical laboratory campus in Mount Pleasant (Vancouver neighbourhood).

It would be a redevelopment of the entire city block …

… earlier today, Vancouver City Council unanimously approved a rezoning enquiry allowing city staff to work with the proponent and accept a formal application for review.

This special additional pre-application step is required due to the temporary ban [emphasis mine] on most types of rezonings within the Broadway Plan’s planning area, until the plan is finalized at the end of 2021.

But city staff are willing to make this a rare exception due to the economic opportunity [emphasis mine] presented by the proposal and the healthcare-related aspects.

“The reasons for advancing this quickly are they are rapidly growing and would like to stay in Vancouver, and we would like them to… We’re very glad to have this company in Vancouver and want to provide them with a permanent home, but in order to scale up, the timeframe to produce their therapy [for viruses] is really time sensitive,” Gil Kelley, the chief urban planner of the City of Vancouver, told city council during today’s [March 10, 2021] meeting.

….

Roughly 10 days after the 2021 budgets are announced, there’s this from Kenneth Chan’s April 29,2021 article on dailyhive.com,

Plans for AbCellera Biologics’ major footprint expansion in Vancouver’s Mount Pleasant Industrial Area are moving forward quickly.

Based on the application submitted this week, the Vancouver-based biotechnology company is proposing to redevelop 110 West 4th Avenue …

It will be designated as the rapidly growing company’s global headquarters.

… city staff are providing AbCellera with the highly rare, expedited stream of combining the rezoning and development application processes into one.

By the middle of this decade, AbCellera will have four locations in the area, including its current 21,000 sq ft office at 2215 Yukon Street and a new 44,000 sq ft office nearing completion at 2131 Manitoba Street, just south of its future main hub.

“We’re building state-of-the-art facilities in Vancouver to accelerate the development of new antibody therapies with biotech and pharma partners from around the world,” said Carl Hansen, CEO and president of AbCellera, in a statement.

AbCellera has gained significant international attention over the past year after it co-developed the first authorized COVID-19 antibody therapy for emergency use in high-risk patients in Canada and the United States.

In late 2020, the company closed a successful initial public offering, bringing in $556 million after selling nearly 28 million shares, far exceeding its original goal of raising $250 million. It was the largest-ever IPO [initial public offering] by a Canadian biotech company.

“We see this new site as a creative hub for engineers, software developers, data scientists, biologists and bioinformaticians to collaborate, innovate, and push the frontiers of technology.” [said Veronique Lecault, the COO of AbCellera]

Additionally, AbCellera is also planning to build a clinical-grade, antibody manufacturing facility in Metro Vancouver, funded in part by the $176-million investment it received from the federal government in Spring 2020 [see May 3, 2020 AbCellera news release].

Not cash but AbCellera did get an expedited process for rezoning and I imagine there will be more special treatment as this progresses. (See the ‘Updates and extras’ at the end of this posting for news about the expedited process.)

It’s likely there are other companies in the BC’s life science sector that are eyeing this development with great interest and high hopes for themselves.

What it takes

COVID-19 seems to have galvanized interest and support almost everywhere in the world for life sciences.

I don’t believe that anyone in the life sciences planned for or rejoiced at news of this pandemic. However, the Canadian biotech sector has been working for decades to establish itself as an important economic resource. and, sadly, COVID-19 has been a timely development.

All those years of lobbying, also known as, government relations, marketing, investor relations, public relations and more served as preparation for what looks like a concerted effort and it has paid off in BC at the federal level, provincial level, and municipal level (at least one).

The campaigns continue. Here’s Wendy Hurlburt, president and CEO of LifeSciences BC in a May 14, 2021 Conversations That Matter Vancouver Sun podcast with Stuart McNish. Note: Hurlburt makes an odd comment at about the 7 min. 30 secs. mark regarding insulin and patents.

Her dismay over lost opportunities regarding the insulin patent is right in line with Canada’s current patent mania. See my May 13, 2021 posting, Not a pretty picture: Canada and a patent rights waiver for COVID-19 vaccines. As far as I’m aware, Canada’s stance has not changed. Interestingly, Hoekstra’s article doesn’t mention COVID-19 patent waivers.

By contrast, here’s what Frederick Banting (one of the discoverers) had to say about his patent, (from the Banting House Insulin Patents webpage),

About the sale of the patent of insulin for $1 Banting reportedly said, “Insulin belongs to the world, not to me.”

… On January 23rd, 1923 Banting, [Charles] Best, and [James] Collip were awarded the American patents for insulin which they sold to the University of Toronto for $1.00 each.

Hurlburt goes on to express dismay over taxes and notes that some companies may leave for other jurisdictions, which means we will lose ‘innovation’. This is a very common ploy coming from any of the technology sectors and can be dated back at least 30 years.

Unmentioned is the dream/business model that so many Canadian tech entrepreneurs have: grow the company, sell it for a lot of money, and retire, preferably before the age of 40.

Getting back to my point, the current situation is not attributable to one individual or to one company’s efforts or to one life science nonprofit or to one federal Network Centre for Excellence (NanoMedicines Innovation Network [NMIN] located at the University of British Columbia).

Note: I have more about the NMIN and Acuitas Therapeutics in a November 12, 2021 posting and there’s more about NMIN’s 7th annual conference and a very high profile guest in a September 11, 2020 posting.

Strategy at the federal, provincial, and local governments, with an eye to the international scene, has been augmented by luck and opportunism.

Updates and extras

Where updates are concerned I have one for Precision Nanosystems and one for AbCellera. I have extras with regard to Moderna and Canada and, BC’s special fund, inBC Investment Corporation. For anyone who’s curious about Banting and the high cost of insulin, I have a couple of links to further reading.

Precision Nanosystems

From an August 11, 2021 article by Kenneth Chan (Note: Links have been removed),

A homegrown pharmaceutical company has announced plans to significantly scale its operations with the opening of a new production facility in Vancouver’s False Creek Flats.

The new Evolution Block building will contain PNI’s new global headquarters and a new genetic medicine Good Manufacturing Practice (GMP) biomanufacturing centre, which would allow the company to expand its capabilities to include the clinical manufacturing of RNA vaccines and therapeutics.

Federal funding totalling $25.1 million for PNI was first announced in February 2021 towards covering part of the development costs of such a facility, as part of the federal government’s new strategy to better ensure Canada has the domestic capacity to secure its own COVID-19 vaccines and prepare the country for future pandemics. It is estimated the vaccine production capacity of the new facility will be 240 million doses annually.

PNI’s location in the False Creek Flats is strategic, given the close proximity to the new St. Paul’s Hospital campus and the growing concentration of tech and healthcare-based industrial businesses.

AbCellera

From a June 22, 2021 article by Kenneth Chan (Note: Links have been removed),

The rapidly growing Vancouver-based biotechnology company announced this morning their 130,000 sq ft Good Manufacturing Practices (GMP) facility will be located on a two-acre site at the 900 block of Evans Avenue, replacing the Urban Beach volleyball courts just next to the City of Vancouver’s Evans maintenance centre and the Regional Recycling Vancouver Bottle Depot.

GMP is partially funded by the $175 million in federal funding received by the company last year to support research into coronavirus treatment.

GMP adds to AbCellera’s major plans to build a new headquarters in close proximity at 110-150 West 4th Avenue in the Mount Pleasant Industrial Area — a city block-sized campus with a total of 380,000 sq ft of laboratory and office space for research and corporate uses.

Both campus buildings are being reviewed under the City of Vancouver’s rare streamlined, expedited process [emphasis mine] of combining the rezoning and development permit applications. AbCellera formally announced its campus plans in April 2021.

AbCellera gained significant international attention last year when it developed the world’s first monoclonal antibody therapy for COVID-19 to be authorized for emergency use in high-risk patients in Canada and the United States. According to the company, over 400,000 doses of its bamlanivimab drug have been administered around the world, and it is estimated to have kept more than 22,000 people out of hospital — saving at least 11,000 lives.

In late 2020, the company closed a successful initial public offering, bringing in $556 million after selling nearly 28 million shares, far exceeding its original goal of raising $250 million. It was the largest-ever IPO by a Canadian biotech company.

Moderna and Canada

It seems like yesterday that Derek Rossi (co-founder of Moderna) was talking about Canada’s need for a biotechnology hub. (see this June 17, 2021 article by Barbara Shecter for the Financial Post). Interestingly, there’s been an announcement of a memorandum of understanding (these things are announced all the time and don’t necessarily result in anything) between Moderna and the government of Canada according to an August 10, 2021 item on the Canadian Broadcasting Corporation (CBC) news website,

Massachusetts-based drug maker Moderna will build an mRNA vaccine manufacturing plant in Canada within the next two years, CEO Stephane Bancel said Tuesday [August 10, 2021; Note the timing, the writ for the next federal election was dropped on August 15, 2021].

The company has signed a memorandum of understanding with the federal government that will result in Canada becoming the home of Moderna’s first foreign operation. It’s not clear yet how much money Canada has offered to Moderna [emphasis mine] for the project.

Canada, whose life sciences industry has been decimated over the last three decades, wants in on the action. Prime Minister Justin Trudeau has promised to rebuild the industry, and the recent budget included a $2.2 billion, seven-year investment to grow the life science and biotech sectors.

Almost half of that targets companies that want to expand or set up vaccine and drug production in Canada. None of the COVID-19 vaccines to date have been made in Canada, leaving the country entirely reliant on imports to fill vaccine orders. As a result, Canada was slower out of the gate on immunizations than some of its counterparts with domestic production, and likely had to pay more per dose for some vaccines as well.

The location of the new facility hasn’t been finalized, but Bancel said the availability of an educated workforce will be the main deciding factor. He said the design is done and they’ll need to start hiring very soon so training can begin.

it’s not exactly a hub but who knows what the future will bring? I imagine there’s going to be some serious wrangling behind the scenes as the provinces battle to be the location for the facility. Note that Innovation Minister François-Philippe Champagne who made the announcement with Bancel in Montréal represents a federal riding in Québec. (BTW, Bancel is from France and seems to have spent much of his adult life in the US.) Of course anything can happen and I’m sure the BC contingent will make themselves felt but it would seem that Quebec is the front runner for now, assuming this memorandum of understanding leads to a facility. Given that we are in the midst of a federal election, it seems more probable than it might otherwise.

inBC Investment Corporation

Bob Mackin’s August 13, 2021 article for theBreaker.news sheds some light on how that corporation was formed so very quickly and more,

The B.C. NDP government rejigged the B.C. Immigrant Investor Fund last year, but refused to release the business case when it was rebranded as inBC Investment Corp. in late April [2021].

theBreaker.news requested the business case for the $500 million fund, which is overseen by a board of NDP patronage appointees, on May 6 [2021].

The 123-page document below is heavily censored — meaning the NDP cabinet is refusing to tell British Columbians the projected operating costs (including board expenses, salary and benefits, office space, operating and administration), full-time equivalents, and cash flows for the newest Crown corporation. inBC bills itself as a triple-bottom line organization, meaning it intends to invest on the basis of social, environmental and economic values.

When its enabling legislation was tabled, the NDP took steps to exempt inBC from the freedom of information law.

Thank you, Mr. Mackin.

More on Banting, insulin and patents

Caitlyn McClure’s 2016 article (Insulin’s Inventor Sold the Patent for $1. Then Drug Companies Got Hold of It.) for other98.com is a brief and pithy explanation for why insulin costs so much. Alanna Mitchell’s August 13, 2019 article for Maclean’s magazine investigates ‘insulin tourism’ and offers more detail as to how this situation has come about.

One last reminder, my August 20, 2021 posting (Getting erased from the mRNA/COVID-19 story) about Ian MacLachlan provides insight into how competitive and rough the bitotechnology scene can be here in BC/Canada.

“Imagine Van Gogh” in Vancouver (Canada) in 2021

Here’s a video about “Imagine Van Gogh,” coming soon to Vancouver, they hope, but which opened first in Montréal in December 2019 where almost 200,000 visited the exhibit before it moved to Winnipeg in March 2020 (Note: There is an advertisement before the Canadian Broadcasting Corporation’s (CBC) segment begins),

The Dec. 7, 2019 CBC news item (where video was embedded), provides more details about the exhibit experience (Note: A link has been removed),

Brushstrokes appear several feet wide, as more than 200 works, such as Starry Night and The Yellow House, are blown up and split into panels, giving visitors a 360-degree view of the paintings projected onto the walls and floor.

Annabelle Mauger, one of the artistic directors behind the exhibit, titled Imagine Van Gogh, says she tests this type of exhibition by seeing how her young children react to it.

“When I saw them just running [at] the image, running into the paintings, I think, this is the most fantastic thing I can do,” she told CBC News.

Mauger said she wanted to create a space where people could experience van Gogh’s art in ways traditional museums don’t allow. Classical music plays as you move around the warehouse space, where you can reach out and touch the simulated canvas or sit on the floor and watch the artwork swirl around you.

That feeling of being surrounded by the artwork is building on French photographer Albert Plécy‘s concept of “image totale,” which Maugler studied while in Provence, France at the Cathédrale d’images.

The Montreal showing of Imagine Van Gogh is its North American debut, with 40,000 tickets sold before it opened at the Arsenal Contemporary Art centre on Dec. 5.

But not everyone is a fan of such immersive art exhibitions, which seek to attract audiences to contemplate works of art by presenting them in an accessible format.

Artist Joseph Nechvatal, reviewing a similar digital art exhibition in Paris titled “Van Gogh, Starry Night,” decried it as “a nasty bit of metaphorical necrophilia” that degrades van Gogh’s daring works.

He called the show “one of the greatest banalizations of painting I have ever seen, matched only by van Gogh kitchen hand towels now being sold around town.”

In that exhibit, the paintings came to life through the use of computer-generated animation. But in Imagine Van Gogh, they retain their static quality as they’re projected on the walls, which lets the art express motion, Mauger says, while still remaining immobile.

“I don’t want the birds flying, you know,” said Mauger. “I don’t want to see the [self]-portrait of van Gogh smoking. No, for me, this is nonsense.”

Hrag Vartanian, the Canadian-raised editor-in-chief and co-founder of the influential art criticism website Hyperallergic, is more generous than Nechvatal in his assessment of the growing trend of immersive digital art shows.

“A lot of these artworks are sometimes disappointing when you’re in a museum and you realize it’s much smaller than you imagined it, or there’s a huge crowd and you don’t get a moment of contemplation you were hoping for,” he said in an interview from New York.

As for the proposed “Imagine Van Gogh” in Vancouver exhibition, Kenneth Chan reveals details about the plans in his Nov. 26, 2020 article for the Daily Hive,

A massive immersive digital art exhibition that blankets tall walls and floors with the projections of works by Vincent van Gogh is slated for Vancouver Convention Centre starting in February 2021.

Plans to bring the exhibition to Vancouver were announced today, but a specific start and end date has yet to be established. The exhibition will operate under the latest public health guidelines in BC.

The exhibition footprint inside the convention centre is 30,000 sq. ft. For context, the total amount of exhibition space at the Vancouver Art Gallery is about 41,000 sq. ft.

There has been immense interest with Imagine Van Gogh in Canada. It received nearly 200,000 visitors in Montreal before it closed in March, and almost 75,000 in Quebec City this past summer during the pandemic. Currently, the exhibition is underway in Winnipeg, and it has been extended to the end of December due to “incredible demand.”

The exhibition is in partnership with France-based Encore Productions and Paquin Entertainment Group and Tandem Expositions.

Organizers are asking interested parties to pre-register. I think they’re trying to gauge the level of interest Vancouverites have in this proposed exhibition. Organizers are offering some incentives to pre-register (from the Vancouver Imagine Van Gogh presale website),

Register now and be the first to know when tickets go on sale, and gain access to an exclusive presale to get tickets before they are available to the general public.

You will also be entered to

win one of three Premiere Packages

for you and three friends to attend the opening of the Imagine Van Gogh exhibit.
 
Additionally, you will receive other exclusive offers from our partners.

Imagine Van Gogh 2020. (Imagine Van Gogh [downloaded from https://dailyhive.com/vancouver/imagine-van-gogh-vancouver-2021]

If you need more inspiration, check out Chan’s Nov. 26, 2020 article where you will find many more images. Enjoy!

‘Smart’ windows in Vancouver (Canada): engineering issues?

This post was going to focus on the first building in Canada to feature ‘smart’ windows. In this case, they are electrochromic windows and the company, View Dynamic Glass, was mentioned here in a September 17, 2018 posting about the windows’ use at the Dallas/Fort Worth Airport. (The posting includes a link to the View Dynamic Glass report on the windows’ use and a short video.)

However, things changed but, first, let’s start with an explanation as to what electrochromic glass ir. Chris Woodford in a December 5, 2018 article on explainthatstuff.com offers a great overview which includes an explanation, a description of how they work, and more. What follows is a brief excerpt from Woodford’s overview (Note: Links have been removed),

What is electrochromic glass?

Glass is an amazing material and our buildings would be dark, dingy, cold, and damp without it. But it has its drawbacks too. It lets in light and heat even when you don’t want it to. On a blinding summer’s day, the more heat (“solar gain”) that enters your building the more you’ll need to use your air-conditioning—a horrible waste of energy that costs you money and harms the environment. That’s why most of the windows in homes and offices are fitted with curtains or blinds. If you’re into interior design and remodeling, you might think furnishings like this are neat and attractive—but in cold, practical, scientific terms they’re a nuisance. Let’s be honest about this: curtains and blinds are a technological kludge to make up for glass’s big, built-in drawback: it’s transparent (or translucent) even when you don’t want it to be.

Since the early 20th century, people have got used to the idea of buildings that are increasingly automated. We have electric clothes washing machines, dishwashers, vacuum cleaners and much more. So why not fit our homes with electric windows that can change from clear to dark automatically? Smart windows (also referred to by the names smart glass, switchable windows, and dynamic windows) do exactly that using a scientific idea called electrochromism, in which materials change color (or switch from transparent to opaque) when you apply an electrical voltage across them. Typically smart windows start off a blueish color and gradually (over a few minutes) turn transparent when the electric current passes through them.

As for the news about its Vancouver debut, I was very excited to see this April 28, 2019 article by Kenneth Chan for dailyhive.com/vancouver,

BlueSky Properties’ 10-storey office building at 988 West Broadway [in Vancouver, Canada; emphasis mine] is home to the new Vancouver offices of Industrial Alliance Financial Group, which has leased nine stories and 93,700-sq-ft of office space.



One of the building’s unique design features is its use of View Dynamic Glass technology [emphases mine] — a glass technology that controls heat and glare, reduces overall energy consumption and costs, and improves the health and wellness of individuals working inside the building.

These smart windows optimize the amount of natural light to enhance mental and physical well-being without the need for shades or blinds. The application of the technology on this building, the first of its kind in Canada, will result in energy savings of up to 20%, [emphasis mine] with the amount of sunlight streaming through automatically tinted to block glare.

Blue Sky Properties (a Bosa Family Company), the local developer for this building, was very excited about the building and the ‘smart’ glass technology, according to its April 23, 2019 news release (here for a short version and here for the full version).

Other than being happy to see the technology being employed in Vancouver, I didn’t spend a lot of time thinking about the property. That changed on reading a May 8, 2019 article by Kenneth Chan for dailyhive.com/vancouver,

A structural engineer based in Vancouver has been stripped of his license to work in British Columbia [emphasis mine] following an investigation that determined his design for a condominium tower in Surrey fell short of the provincial building code.

According to a disciplinary notice posted by Engineers and Geoscientists British Columbia Association (EGBCA) on April 30, John Bryson, a managing partner of Bryson Markulin Zickmantel Structural Engineers (BMZSE), [emphases mine] admitted to unprofessional conduct and acted contrary to the association’s code of ethics that requires its members to “hold paramount the safety, health, and welfare of the public.”

“Mr. Bryson admitted that his structural design for the building did not comply with the 2006 BC Building Code, to which he certified it had been designed, in particular with respect to seismic and wind loads,” reads the notice. [emphases mine]

BMZSE has been involved in the design work of a number of projects across Metro Vancouver, including Station Square, Rogers Arena South Tower, Lougheed Heights, River District Parcel 17, The Jervis, Harwood, Plaza 88, Solo District, Burrard Place, Centreview Place, Trump International Hotel & Tower Vancouver, Central, Sovereign, Kings Crossing, and 988 West Broadway. [emphases mine]

You can find the ‘disciplinary notice’ (it’s an account of what Bryson failed to do and the punishment for the failure) here on the Association of Professional Engineers and Geoscientists of the Province of British Columbia (also known as Engineers and Geoscientists British Columbia) website.

Presumably, all of Bryson’s projects have been reviewed since the disciplinary action.

2018 Canadian Science Policy Conference (Nov. 7 – 9, 2018) highlights and Council of Canadian Academies: a communications job, a report, and more

This is a going to a science policy heavy posting with both a conference and the latest report from the Canadian Council of Academies (CCA).

2018 Canadian Science Policy Conference

As I noted in my March 1, 2018 posting, this is the fourth year in a row that the conference is being held in Ottawa and the theme for this 10th edition is ‘Building Bridges Between Science, Policy and Society‘.

The dates are November 7 -9, 2018 and as the opening draws closer I’m getting more ‘breathlessly enthusiastic’ announcements. Here are a few highlights from an October 23, 2018 announcement received via email,

CSPC 2018 is honoured to announce that the Honourable Kirsty Duncan, Minister of Science and Sport, will be delivering the keynote speech of the Gala Dinner on Thursday, November 8 at 7:00 PM. Minister Duncan will also hand out the 4th Science Policy Award of Excellence to the winner of this year’s competition.

CSPC 2018 features 250 speakers, a record number, and above is the breakdown of the positions they hold, over 43% of them being at the executive level and 57% of our speakers being women.

*All information as of October 15, 2018

If you think that you will not meet any new people at CSPC and all of the registrants are the same as last year, think again!

Over 57% of  registrants are attending the conference for the FIRST TIME!

Secure your spot today!

*All information as of October 15, 2018

Here’s more from an October 31, 2018 announcement received via email,

One year after her appointment as Canada’s Chief Science Advisor, Dr. Mona Nemer will discuss her experience with the community. Don’t miss this opportunity.

[Canadian Science Policy Centre editorials in advance of conference]

Paul Dufour
“Evidence and Science in Parliament–Looking Back at CSPC and Moving Forward”

Dr. Tom Corr
“Commercializing Innovation in Canada: Advancing in the Right Direction”

Joseph S Sparling, PhD
“Reimagining the Canadian Postdoctoral Training System”

Milton Friesen
“Conspiring Together for Good: Institutional Science and Religion”

Joseph Tafese
“Science and the Next Generation : Science and Inclusivity, Going beyond the Slogans”

Eva Greyeyes
“Opinion Editorial for CSPC, November 2018”

Monique Crichlow
Chris Loken

“Policy Considerations Towards Converged HPC-AI Platforms”

Should you be in the Ottawa area November 7 – 9, 2018, it’s still possible to register.

**Update November 6, 2018: The 2018 CSPC is Sold Out!**

Council of Canadian Academies: job and the ‘managing innovation’ report

Let’s start with the job (from the posting),

October 17, 2018

Role Title:      Director of Communications
Deadline:       November 5, 2018
Salary:            $115,000 to $165,000

About the Council of Canadian Academies
The Council of Canadian Academies (CCA) is a not-for-profit organization that conducts assessments of evidence on scientific topics of public interest to inform decision-making in Canada.

Role Summary
The CCA is seeking an experienced communications professional to join its senior management team as Director of Communications. Reporting to the President and CEO, the Director is responsible for developing and implementing a communications plan for the organization that promotes and highlights the CCA’s work, brand, and overall mission to a variety of potential users and stakeholders; overseeing the publication and dissemination of high-quality hard copy and online products; and providing strategic advice to the President and CCA’s Board, Committees, and Panels. In fulfilling these responsibilities, the Director of Communications is expected to work with a variety of interested groups including the media, the broad policy community, government, and non-governmental organizations.

Key Responsibilities and Accountabilities
Under the direction of the President and CEO, the Director leads a small team of communications and publishing professionals to meet the responsibilities and accountabilities outlined below.

Strategy Development and External Communications
• Develop and execute an overall strategic communications plan for the organization that promotes and highlights the CCA’s work, brand, and overall mission.
• Oversee the CCA’s presence and influence on digital and social platforms including the development and execution of a comprehensive content strategy for linking CCA’s work with the broader science and policy ecosystem with a focus on promoting and disseminating the findings of the CCA’s expert panel reports.
• Provide support, as needed for relevant government relations activities including liaising with communications counterparts, preparing briefing materials, responding to requests to share CCA information, and coordinating any appearances before Parliamentary committees or other bodies.
• Harness opportunities for advancing the uptake and use of CCA assessments, including leveraging the strengths of key partners particularly the founding Academies.

Publication and Creative Services
• Oversee the creative services, quality control, and publication of all CCA’s expert panel reports including translation, layout, quality assurance, graphic design, proofreading, and printing processes.
• Oversee the creative development and publication of all CCA’s corporate materials including the Annual Report and Corporate Plan through content development, editing, layout, translation, graphic design, proofreading, and printing processes.

Advice and Issues Management
• Provide strategic advice and support to the President’s Office, Board of Directors, Committees, and CCA staff about increasing the overall impact of CCA expert panel reports, brand awareness, outreach opportunities, and effective science communication.
• Provide support to the President by anticipating project-based or organizational issues, understanding potential implications, and suggesting strategic management solutions.
• Ensure consistent messages, style, and approaches in the delivery of all internal and external communications across the organization.

Leadership
• Mentor, train, and advise up to five communications and publishing staff on a day-to-day basis and complete annual performance reviews and planning.
• Lead the development and implementation of all CCA-wide policy and procedures relating to all aspects of communications and publishing.
• Represent the issues, needs, and ongoing requirements for the communications and publishing staff as a member of the CCA senior management team.

Knowledge Requirements
The Director of Communications requires:
• Superior knowledge of communications and public relations principles – preferably as it applies in a non-profit or academic setting;
• Extensive experience in communications planning and issues management;
• Knowledge of current research, editorial, and publication production standards and procedures including but not limited to: translation, copy-editing, layout/design, proofreading and publishing;
• Knowledge of evaluating impact of reports and assessments;
• Knowledge in developing content strategy, knowledge mobilization techniques, and creative services and design;
• Knowledge of human resource management techniques and experience managing a team;
• Experience in coordinating, organizing and implementing communications activities including those involving sensitive topics;
• Knowledge of the relationships and major players in Canada’s intramural and extramural science and public policy ecosystem, including awareness of federal science departments and Parliamentary committees, funding bodies, and related research groups;
• Knowledge of Microsoft Office Suite, Adobe Creative Suite, WordPress and other related programs;
• Knowledge of a variety of social media platforms and measurement tools.

Skills Requirements
The Director of Communications must have:
• Superior time and project management skills
• Superior writing skills
• Superior ability to think strategically regarding how best to raise the CCA’s profile and ensure impact of the CCA’s expert panel reports
• Ability to be flexible and adaptable; able to respond quickly to unanticipated demands
• Strong advisory, negotiation, and problem-solving skills
• Strong skills in risk mitigation
• Superior ability to communicate in both written and oral forms, effectively and diplomatically
• Ability to mentor, train, and provide constructive feedback to direct reports

Education and Experience
This knowledge and skillset is typically obtained through the completion of a post-secondary degree in Journalism, Communications, Public Affairs or a related field, and/or a minimum of 10
years of progressive and related experience. Experience in an organization that has addressed topics in public policy would be valuable.

Language Requirements: This position is English Essential. Fluency in French is a strong asset.

To apply to this position please send your CV and cover letter to careers@scienceadvice.ca before November 5, 2018. The cover letter should answer the following questions in 1,000 words or less:

1. How does your background and work experience make you well-suited for the position of Director of Communications at CCA?
2. What trends do you see emerging in the communications field generally, and in science and policy communications more specifically? How might CCA take advantage of these trends and developments?
3. Knowing that CCA is in the business of conducting assessments of evidence on important policy topics, how do you feel communicating this type of science differs from communicating other types of information and knowledge?

Improving Innovation Through Better Management

The Council of Canadian Academies released their ‘Improving Innovation Through Better Management‘ report on October 18, 2018..As some of my regular readers (assuming there are some) might have predicted, I have issues.

There’s a distinct disconnection between the described problem and the questions to be answered. From the ‘Improving Innovation Through Better Management‘ summary webpage,

While research is world-class and technology start-ups are thriving, few companies grow and mature in Canada. This cycle — invent and sell, invent and sell — allows other countries to capture much of the economic and social benefits of Canadian-invented products, processes, marketing methods, and business models. …

So, the problem is ‘invent and sell’. Leaving aside the questionable conclusion that other countries are reaping the benefits of Canadian innovation (I’ll get back to that shortly), what questions could you ask about how to break the ‘invent and sell, invent and sell’ cycle? Hmm, maybe we should ask, How do we break the ‘invent and sell’ cycle in Canada?

The government presented two questions to deal with the problem and no, how to break the cycle is not one of the questions. From the ‘Improving Innovation Through Better Management‘ summary webpage,

… Escaping this cycle may be aided through education and training of innovation managers who can systematically manage ideas for commercial success and motivate others to reimagine innovation in Canada.

To understand how to better support innovation management in Canada, Innovation, Science and Economic Development Canada (ISED) asked the CCA two critical questions: What are the key skills required to manage innovation? And, what are the leading practices for teaching these skills in business schools, other academic departments, colleges/polytechnics, and industry?

As lawyers, journalists, scientists, doctors, librarians, and anyone who’s ever received misinformation can tell you, asking the right questions can make a big difference.

As for the conclusion that other countries are reaping the benefits of Canadian innovation, is there any supporting data? We enjoy a very high standard of living and have done so for at least a couple of generations. The Organization for Economic Cooperation and Development (OECD) has a Better Life Index, which ranks well-being on these 11 dimensions (from the OECD Better Life Index entry on Wikipedia), Note: Links have been removed,

  1. Housing: housing conditions and spendings (e.g. real estate pricing)
  2. Income: household income and financial wealth
  3. Jobs: earnings, job security and unemployment
  4. Community: quality of social support network
  5. Education: education and what you get out of it
  6. Environment: quality of environment (e.g. environmental health)
  7. Governance: involvement in democracy
  8. Health
  9. Life Satisfaction: level of happiness
  10. Safety: murder and assault rates
  11. Work-life balance

In 2017, the index ranked Canada as fifth in the world while the US appears to have slipped from a previous ranking of 7th to 8th. (See these Wikipedia entries with relevant subsections for rankings:  OECD Better Life Index; Rankings, 2017 ranking and Standard of living in the United States, Measures, 3rd paragraph.)

This notion that other countries are profiting from Canadian innovation while we lag behind has been repeated so often that it’s become an article of faith and I never questioned it until someone else challenged me. This article of faith is repeated internationally and sometimes seems that every country in the world is worried that someone else will benefit from their national innovation.

Getting back to the Canadian situation, we’ve decided to approach the problem by not asking questions about our article of faith or how to break the ‘invent and sell’ cycle. Instead of questioning an assumption and producing an open-ended question, we have these questions (1) What are the key skills required to manage innovation? (2) And, what are the leading practices for teaching these skills in business schools, other academic departments, colleges/polytechnics, and industry?

in my world that first question, would be a second tier question, at best. The second question, presupposes the answer: more training in universities and colleges. I took a look at the report’s Expert Panel webpage and found it populated by five individuals who are either academics or have strong ties to academe. They did have a workshop and the list of participants does include people who run businesses, from the Improving Innovation Through Better Management‘ report (Note: Formatting has not been preserved),

Workshop Participants

Max Blouw,
Former President and Vice-Chancellor of
Wilfrid Laurier University (Waterloo, ON)

Richard Boudreault, FCAE,
Chairman, Sigma Energy
Storage (Montréal, QC)

Judy Fairburn, FCAE,
Past Board Chair, Alberta Innovates;
retired EVP Business Innovation & Chief Digital Officer,
Cenovus Energy Inc. (Calgary, AB)

Tom Jenkins, O.C., FCAE,
Chair of the Board, OpenText
(Waterloo, ON)

Sarah Kaplan,
Director of the Institute for Gender and the
Economy and Distinguished Professor, Rotman School of
Management, University of Toronto (Toronto, ON)

Jean-Michel Lemieux,
Senior Vice President of Engineering,
Shopify Inc. (Ottawa, ON)

Elicia Maine,
Academic Director and Professor, i2I, Beedie
School of Business, Simon Fraser University (Vancouver, BC)

Kathy Malas,
Innovation Platform Manager, CHU
Sainte Justine (Montréal, QC)

John L. Mann, FCAE,
Owner, Mann Consulting
(Blenheim, ON)

Jesse Rodgers,
CEO, Volta Labs (Halifax, NS)

Creso Sá,
Professor of Higher Education and Director of
the Centre for the Study of Canadian and International
Higher Education, Ontario Institute for Studies in Education,
University of Toronto (Toronto, ON)

Dhirendra Shukla,
Professor and Chair, J. Herbert Smith
Centre for Technology Management & Entrepreneurship,
Faculty of Engineering, University of New Brunswick
(Fredericton, NB)

Dan Sinai,
Senior Executive, Innovation, IBM Canada
(Toronto, ON)

Valerie Walker,
Executive Director, Business/Higher
Education Roundtable (Ottawa, ON)

J. Mark Weber,
Eyton Director, Conrad School of
Entrepreneurship & Business, University of Waterloo
(Waterloo, ON)

I am a little puzzled by the IBM executive’s presence (Dan Sinai) on this list. Wouldn’t Canadians holding onto their companies be counterproductive to IBM’s interests? As for John L. Mann, I’ve not been able to find him or his consulting company online. it’s unusual not to find any trace of an individual or company online these days.

In all there were nine individuals representing academic or government institutions in this list. The gender balance is 10 males and five females for the workshop participants and three males and two females for the expert panel. There is no representation from the North or from Manitoba, Saskatchewan, Prince Edward Island, or Newfoundland.

If they’re serious about looking at how to use innovation to drive higher standards of living, why aren’t there any people from Asian countries where they have been succeeding at that very project? South Korea and China come to mind.

I’m sure there are some excellent ideas in the report, I just wish they’d taken their topic to heart and actually tried to approach innovation in Canada in an innovative fashion.

Meanwhile, Vancouver gets another technology hub, from an October 30, 2018 article by Kenneth Chan for the Daily Hive (Vancouver [Canada]), Note: Links have been removed,

Vancouver’s rapidly growing virtual reality (VR) and augmented reality (AR) tech sectors will greatly benefit from a new VR and AR hub created by Launch Academy.

The technology incubator has opened a VR and AR hub at its existing office at 300-128 West Hastings Street in downtown, in partnership with VR/AR Association Vancouver. Immersive tech companies have access to desk space, mentorship programs, VR/AR equipment rentals, investor relations connected to Silicon Valley [emphasis mine], advisory services, and community events and workshops.

Within the Vancouver tech industry, the immersive sector has grown from 15 companies working in VR and AR in 2015 to 220 organizations today.

Globally, the VR and AR market is expected to hit a value of $108 billion by 2021, with tech giants like Amazon, Apple, Facebook, Google, and Microsoft [emphasis mine] investing billions into product development.

In the Vancouver region, the ‘invent and sell’ cycle can be traced back to the 19th century.

One more thing, as I was writing this piece I tripped across this news: “$7.7-billion pact makes Encana more American than Canadian‘ by Geoffrey Morgan. It’s in the Nov. 2, 2018 print edition of the Vancouver Sun’s front page for business. “Encana Corp., the storied Canadian company that had been slowly transitioning away from Canada and natural gas over the past few years under CEO [Chief Executive Officer] Doug Suttles, has pivoted aggressively to US shale basins. … Suttles, formerly as BP Plc. executive, moved from Calgary [Alberta, Canada] to Denver [Colorado, US], though the company said that was for personal reasons and not a precursor to relocation of Encana’s headquarters.”  Yes, that’s quite believable. By the way, Suttles has spent* most of his life in the US (Wikipedia entry).

In any event, it’s not just Canadian emerging technology companies that get sold or somehow shifted out of Canada.

So, should we break the cycle and, if so, how are we going to do it?

*’spend’ corrected to ‘spent’ on November 6, 2018.

High speed rail link for Cascadia Innovation Corridor

In a Feb. 28, 2017 posting I featured an announcement about what I believe is the first  project from the British Columbia (province of Canada) and Washington State (US) government’s joint Cascadia Innovation Corridor initiative:  the Cascadia Analytics Cooperative, During the telephone press conference a couple of the participants joked about hyperloop (transportation pods in vacuum tubes) and  being able to travel between Vancouver (Canada) and Seattle (US) in minutes. It seems that might not have been quite the joke I assumed. Kenneth Chan in an Aug. 14, 2017 posting for the Daily Hive announced a high-speed rail feasibility study is underway (Note: Links have been removed),

According to KUOW public radio, the study began in late-July and will be conducted by a consultant at a cost of US$300,000 – down from the budgeted USD$1 million when the study was first announced earlier this year in Governor Jay Inslee’s proposed state budget. The budget bill proposed Washington State stations at locations such as Bellingham, Everett, SeaTac International Airport, Tacoma, Olympia, and Vancouver, Washington.

The idea has received the full backing of Washington State-based Microsoft, which supported the study with an additional $50,000 contribution. [emphasis mine] Engineering consultancy firm CH2M, which has offices in Vancouver, Seattle, and Portland, has been contracted to perform the study.

Interest in such a rail link is spurred from the Cascadia Innovation Corridor agreement signed by the government leaders of BC and Washington State last fall. The agreement committed both jurisdictions to growing the Vancouver-Seattle corridor into a tech corridor and innovation hub and improving transportation connections, such as high-speed rail.

“Why not a high speed train from Vancouver to Seattle to Portland? If we lived in Europe it would already be there,” said Brad Smith, Microsoft President and Chief Legal Officer, at a recent Portland conference on regional policy. “We need to raise our sights and our ambition level as a region.”

Microsoft is very interested in facilitating greater ease of movement, a development which causes me to to feel some unease as mentioned in my February 28, 2017 posting,

I look forward to hearing more about the Cascadia Urban Analytics Cooperative and the Cascadia Innovation Corridor as they develop. This has the potential to be very exciting although I do have some concerns such as MIcrosoft and its agendas, both stated and unstated. After all, the Sept. 2016 meeting was convened by Microsoft and its public affairs/lobbying group and the topic was innovation, which is code for business and as hinted earlier, business is not synonymous with social good. Having said that I’m not about to demonize business either. I just think a healthy dose of skepticism is called for. Good things can happen but we need to ensure they do.

Since February 2017, the government in British Columbia has changed hands and is now led by James Horgan of the New Democratic Party. Like Christy Clark and the Liberals before them, this provincial government does not have any science policy, a ministry of science (senior or junior), or any evidence of independent science advice. There has been (and may still be, it’s hard to tell) a Premier’s Technology Council, a BC Innovation Council (formerly the Science Council of BC), and #BCTECH Strategy which hie more to business and applied science than an inclusive ‘science strategy’ with attendant government agencies.